Leinco Technologies, Inc.
excellence in early discovery research™

Mouse IFNAR-1 Antibody

Purified *in vivo* PLATINUM™ Functional Grade
Monoclonal Antibody

Product Information

Product No.:	I-1188
Clone:	MAR1-5A3
RRID:	AB_2830518
Isotype:	Mouse IgG1
Storage:	Sterile 2-8°C

Lane 1: 20 ug reduced A-20 whole cell lysate (Prod. No. A232)

Lane 2: 10 ug reduced A-20 whole cell lysate (Prod. No. A232)

Lane 3: 1 ug reduced recombinant mouse IFNAR-1

Lane 4: 0.5 ug reduced recombinant mouse IFNAR-1

Primary: anti-mouse IFNAR-1antibody (MAR1-5A3) at 8 ug/ml (Prod. No. I-1188)

Secondary: HRP labeled goat anti-mouse at 1:1000 dilution (Prod. No. M114)

Predicted band size: 60-70 kDa

Product Description

Specificity:

Clone MAR1-5A3 recognizes an epitope on mouse IFNAR1.

Antigen Distribution:

IFNAR1 and IFNAR2 are coexpressed on nearly all cells.

Background:

IFNAR1 is a type I membrane protein, that in conjunction with IFNAR2, makes up the heterodimeric receptor that binds all type I IFNs, which includes IFN α and β. Binding and activation of the receptor stimulates Janus protein kinases, which leads to the phosphorylation of several other proteins, namely STAT1 and STAT2. IFNAR1 has also been shown to interact with PRMT1 and Tyrosine kinase 2. Type I IFNs are a family of cytokines that have been shown to promote anti-viral, anti-microbial, anti-tumor and autoimmune responses *In vivo*.

Known Reactivity Species:

Mouse

Format:

Purified *in vivo* PLATINUM™ Functional Grade

Immunogen:

Plasmid DNA encoding murine IFNAR1 extracellular domain

Formulation

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Purity

≥98% monomer by analytical SEC, >95% by SDS Page

Endotoxin

<0.5 EU/mg as determined by the LAL method

Storage and Stability

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminister Dr, St. Louis, MO 63026   (800) 538-1145   leincoglobal@leinco.com

Product Preparation

Functional grade preclinical antibodies are manufactured in an animal free facility using *in vitro* cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Pathogen Testing

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco's Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Applications

Applications and Recommended Usage (Quality Tested By Leinco):

FC The suggested concentration for clone MAR1-5A3 antibody for staining cells in flow cytometry is ≤ 2.0 µg per 10^6 cells in a volume of 100 µl or 100µl of whole blood. Titration of the reagent is recommended for optimal performance for each application.

Other Applications Reported in Literature:

B Clone MAR1-5A3 has a short half-life due to the rapid recycling of cells that express the IFNAR1 receptor. In order to block function *In vivo*, continual blocking of all compartments is necessary. Therefore, a large loading dose is necessary to saturate all *In vivo* binding sites and should be maintained to ensure binding site saturation. For *In vivo* blocking studies, a loading dose of 2.5 mg/mouse, followed by a weekly dose of 0.5 mg/mouse is recommended. The half-life following a 2.5 mg loading dose is approximately 5 days. However, if you fail to saturate the binding sites by injecting a low dose of 250 µg, for example, the half life is only 1.5 days.

WB

IP

ELISA

Country of Origin

USA

References

1.) Beaver, Jacob T. *et al.* (2020) *Human Vaccines & Immunotherapeutics* 16:9, 2092-2108 Article Link

2.) Theofilopoulos, AN. *et al.* (2012) *J Immunol.* 189: 000–000. Article Link

3.) Oldstone, Michael B. A. *et al.* (2017) *Proc Natl Acad Sci U S A.* 114(14): 3708–3713. PubMed

4.) Schreiber, RD *et al.* (2015) *PLoS One.*10(5):e0128636PubMed

5.) Shin, Haina *et al.* (2018) *J Virol.* 92(7): e00038-18. PubMed

6.) Crack, Peter J. *et al.* (2016) *eNeuro* 10.1523/ENEURO.0128-15.2016 Article Link

7.) Sheehan, K. C. F. *et al.* (2006) *JICR* 26(11):804

8.) Dunn, G. P. *et al.* (2005) *Nat. Immunol.* 6(7):722

9.) Fenner, J. E. *et al.* (2006) *Nat. Immunol.* 7(1):33

10.) Biron, C. A. *et al.* (2007) *J Exp Med.* 204(10): 2383

11.) Sharma S. *et al.* (2020) *Human Vaccines & Immunotherapeutics* 16(9):2196-2203 Journal Link

12.) Cliffe, A. *et al.* (2021) *EMBO Reports* 22(9):e52547 Journal Link

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

410 Axminister Dr, St. Louis, MO 63026   (800) 538-1145   leincoglobal@leinco.com